These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

228 related articles for article (PubMed ID: 25984995)

  • 41. Effect of exposure to injection drugs or alcohol on antigen-specific immune responses in HIV and hepatitis C virus coinfection.
    Graham CS; Wells A; Edwards EM; Herren T; Tumilty S; Stuver SO; Samet JH; Nunes D; Horsburgh CR; Koziel MJ
    J Infect Dis; 2007 Mar; 195(6):847-56. PubMed ID: 17299715
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Changes in quality of life, healthcare use, and substance use in HIV/hepatitis C coinfected patients after hepatitis C therapy: a prospective cohort study.
    Yeung MW; Young J; Moodie E; Rollet-Kurhajec KC; Schwartzman K; Greenaway C; Cooper C; Cox J; Gill J; Hull M; Walmsley S; Klein MB
    HIV Clin Trials; 2015; 16(3):100-10. PubMed ID: 25972048
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Impulsive choice predicts short-term relapse in substance-dependent individuals attending an in-patient detoxification programme.
    Stevens L; Goudriaan AE; Verdejo-Garcia A; Dom G; Roeyers H; Vanderplasschen W
    Psychol Med; 2015 Jul; 45(10):2083-93. PubMed ID: 25640022
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Delay discounting and substance use treatment outcomes: A systematic review focused on treatment outcomes and discounting methodology.
    Exum AC; Sutton CA; Bellitti JS; Yi R; Fazzino TL
    J Subst Use Addict Treat; 2023 Jun; 149():209037. PubMed ID: 37072099
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Predictors of treatment for hepatitis C virus (HCV) infection in drug users.
    Reed C; Stuver SO; Tumilty S; Nunes D; Murray JE; Graham CS; James Koziel M; Craven DE; Skolnik PR; Horsburgh CR
    Subst Abus; 2008; 29(1):5-15. PubMed ID: 19042314
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Effects of substance use on monetary delay discounting among people who use stimulants with and without HIV: An ecological momentary assessment study.
    Xu Y; Towe SL; Causey ST; Dennis PA; Meade CS
    Exp Clin Psychopharmacol; 2022 Feb; 30(1):39-50. PubMed ID: 32757596
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Prevalence and associated clinical characteristics of hepatitis B, C, and HIV infections among injecting drug users in Korea.
    Min JA; Yoon Y; Lee HJ; Choi J; Kwon M; Kim K; Lee CU; Kim DJ; Yun H
    J Med Virol; 2013 Apr; 85(4):575-82. PubMed ID: 23364858
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Longitudinal pathways linking family risk, neural risk processing, delay discounting, and adolescent substance use.
    Kim-Spoon J; Lauharatanahirun N; Peviani K; Brieant A; Deater-Deckard K; Bickel WK; King-Casas B
    J Child Psychol Psychiatry; 2019 Jun; 60(6):655-664. PubMed ID: 30809804
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Understanding differences in HIV/HCV prevalence according to differentiated risk behaviors in a sample of PWID in rural Puerto Rico.
    Abadie R; Welch-Lazoritz M; Gelpi-Acosta C; Reyes JC; Dombrowski K
    Harm Reduct J; 2016 Mar; 13():10. PubMed ID: 26956029
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Delay Discounting of Losses in Alcohol Use Disorders and Antisocial Psychopathology: Effects of a Working Memory Load.
    Gerst KR; Gunn RL; Finn PR
    Alcohol Clin Exp Res; 2017 Oct; 41(10):1768-1774. PubMed ID: 28792623
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [Limited impact of the harm-reduction policy on HCV among drug-users. The ANRS-Coquelicot survey example].
    Jauffret-Roustide M; Emmanuelli J; Desenclos JC
    Rev Epidemiol Sante Publique; 2006 Jul; 54 Spec No 1():1S53-1S59. PubMed ID: 17073130
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Adaptation of the Monetary Choice Questionnaire to accommodate extreme monetary discounting in cocaine users.
    Towe SL; Hobkirk AL; Ye DG; Meade CS
    Psychol Addict Behav; 2015 Dec; 29(4):1048-55. PubMed ID: 26191820
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Impulsive Decision Making in Young Adult Social Drinkers and Detoxified Alcohol-Dependent Patients: A Cross-Sectional and Longitudinal Study.
    Bernhardt N; Nebe S; Pooseh S; Sebold M; Sommer C; Birkenstock J; Zimmermann US; Heinz A; Smolka MN
    Alcohol Clin Exp Res; 2017 Oct; 41(10):1794-1807. PubMed ID: 28815629
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Prevalence of HIV, HCV, and High-Risk Behaviors for Substance Users in Drop in Centers in Southern Iran.
    Salehi A; Naghshvarian M; Marzban M; Bagheri Lankarani K
    J Addict Med; 2015; 9(3):181-7. PubMed ID: 25748560
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Application of a Brief Measure of Delay Discounting to Examine the Relationship Between Delay Discounting and the Initiation of Substance Use Among Adolescents.
    Richardson CG; Edalati H
    Subst Use Misuse; 2016; 51(4):540-4. PubMed ID: 26943476
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Prevalence of HIV and hepatitis C virus infections among inmates of Quebec provincial prisons.
    Poulin C; Alary M; Lambert G; Godin G; Landry S; Gagnon H; Demers E; Morarescu E; Rochefort J; Claessens C
    CMAJ; 2007 Jul; 177(3):252-6. PubMed ID: 17664448
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Incarceration and infection: drug policy in the USA.
    Burki T
    Lancet Infect Dis; 2017 Jul; 17(7):697. PubMed ID: 28737490
    [No Abstract]   [Full Text] [Related]  

  • 58. Does Pain Affect Preference? The Effect of Tonic Laboratory Pain on Discounting of Delayed Rewards.
    Rassu FS; Linsenbardt HR; Fields SA; Meagher MW
    J Pain; 2018 Sep; 19(9):962-972. PubMed ID: 29601897
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Co-Infection Burden of Hepatitis C Virus and Human Immunodeficiency Virus among Injecting Heroin Users at the Kenyan Coast.
    Mwatelah RS; Lwembe RM; Osman S; Ogutu BR; Aman R; Kitawi RC; Wangai LN; Oloo FA; Kokwaro GO; Ochieng W
    PLoS One; 2015; 10(7):e0132287. PubMed ID: 26208212
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Significant reductions in alcohol use after hepatitis C treatment: results from the ANRS CO13-HEPAVIH cohort.
    Knight R; Roux P; Vilotitch A; Marcellin F; Rosenthal E; Esterle L; Boué F; Rey D; Piroth L; Dominguez S; Sogni P; Salmon-Ceron D; Spire B; Carrieri MP;
    Addiction; 2017 Sep; 112(9):1669-1679. PubMed ID: 28430385
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.